RWJ 67657 – 1 mg

Brand:
Cayman
CAS:
215303-72-3
Storage:
-20
UN-No:
Non-Hazardous - /

RWJ 67657 is an orally active inhibitor of the MAP kinases p38α and p38β (IC50s = 1 and 11 µM, respectively, in vitro) that is inactive against p38γ and p38δ, as well as several other kinases.{30330} It blocks the release of TNF-α and IL-1β from peripheral blood mononuclear cells stimulated with LPS (IC50s = 3 and 11 nM, respectively) and inhibits TNF-α production in LPS-treated mice and rats.{30330} RWJ 67657 potently blocks the proliferation of CD4+ peripheral blood T cells induced by CD28 stimulation alone (IC50 = 0.5-4 nM).{30329} It is commonly used to study the roles of p38α and p38β in cellular and whole animal systems.{30328,30326,30327}  

 

Available on backorder

SKU: - Category:

Description

An orally active, selective inhibitor of p38α and p38β (IC50s = 1 and 11 µM, respectively, in vitro); blocks the release of TNF-α and IL-1β from peripheral blood mononuclear cells stimulated with LPS (IC50s = 3 and 11 nM, respectively) and inhibits TNF-α production in LPS-treated mice and rats


Formal name: 4-[4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-3-butyn-1-ol

Synonyms:  JNJ-3026582

Molecular weight: 425.5

CAS: 215303-72-3

Purity: ≥95%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors|p38 MAPK||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cell Biology|Cell Signaling|p38 MAPK Signaling||Research Area|Immunology & Inflammation|Adaptive Immunity||Research Area|Immunology & Inflammation|Innate Immunity